(Q51068076)

28 March 2018

title

Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. (English)

1 reference

28 March 2018

1 reference

acute myeloid leukemia

1 reference

4

Bjørn Tore Gjertsen

1 reference

28 March 2018

2

Ina Nepstad

1 reference

28 March 2018

Håkon Reikvam

1

1 reference

28 March 2018

André Sulen

series ordinal

3

1 reference

28 March 2018

Kimberley Joanne Hatfield

series ordinal

5

1 reference

28 March 2018

Øystein Bruserud

series ordinal

6

1 reference

28 March 2018

language of work or name

English

0 references

publication date

1 May 2013

1 reference

28 March 2018

Expert Opinion on Investigational Drugs

published in

1 reference

28 March 2018

volume

22

1 reference

28 March 2018

issue

5

1 reference

28 March 2018

page(s)

551-563

1 reference

28 March 2018

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Reduced mortality after allogeneic hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Acute myeloid leukaemia in the elderly: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Clinical correlation of circulating heat shock protein 70 in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Death by chaperone: HSP90, HSP70 or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

The nuclear factor erythroid 2-like 2 activator, tert-butylhydroquinone, improves cognitive performance in mice after mild traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.791280

10.1517/13543784.2013.791280

21 January 2018

Identifiers

DOI

1 reference

28 March 2018

1 reference

28 March 2018